This is an editorial which emphasizes the role of rFVIIa in treating hemophilia patients with inhibitors to factors VIII or IX. It also highlights the increasing role of rFVIIa in the treatment of severe bleeding in non-hemohilia patients, such as patients with deranged coagulation due to liver disease, sepsis or platelet dysfunction. It emphasizes the importance of studying the use of rFVIIa within large randomized studies rather than relying on anecdotal data and small series case reports.

– Maadh Aldouri